References
- Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Piroxicam: review of its pharmacological properties and therapeutic efficacy. Drugs 1981; 22: 165–187
- Esteve A., Martinez L., Roser R., Sagarra R. Pharmacokinetics of droxicam in rat and dog. Methods and Findings in Experimental Clinical Pharmacology 1986; 8: 423–429
- Hobbs D. C. Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex, and adverse effects. American Journal of Medicine 1986; 81: 22–28, (Suppl. 5B)
- Ligniere G. C., Montagnini G., Alberici M., Acerbi D. Plasma and synovial fluid concentrations of piroxicam during prolonged treatment with piroxicam pivalic ester,. Arzneimittel Forschung/Drug Research 1987; 37: 560–563
- Marfat A., Carty T. J., Moore P. F., Twomey T. M., Weissman A. (1988) Synthesis and pharmacokinetics of ampiroxicam and related prodrugs of piroxicam. Fourth International Conference of the Inflammation Research Association, Abstract 73, Whitehaven, PA, October, 23-271988
- Swahn A. On the absorption of 35S-ampicillin. European Journal of Clinical Pharmacology 1975; 8: 117–124
- Swahn A. Gastrontestinal absorption and metabolism of two 35S-labeled ampicillin esters. European Journal of Clinical Pharmacology 1976; 9: 299–306
- Twomey T., Bartolucci S., Hobbs D. Analysis of piroxicam in plasma by high performance liquid chromatography. Journal of Chromatography 1980; 183: 104–108